Clinical Trial Update: SU5416 in Treating Patients With Refractory or Relapsed Multiple Myeloma [Phase 2]

View source ↗

Summary

This is a Phase 2 clinical trial update on SU5416 for patients with refractory or relapsed multiple myeloma, with the study status noted as completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma
• Plasma Cell Neoplasm

Drugs mentioned

• SU5416 (semaxanib)

Snippet

Sponsor: Fox Chase Cancer Center | Conditions: Multiple Myeloma and Plasma Cell Neoplasm | Phase 2 | Status: COMPLETED